Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of oral dersimelagon in EPP or XLP
2024-514466-38-00Phase 3Authorised
- Sponsor
- Mitsubishi Tanabe Pharma America
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma America. Primary endpoints: Treatment-emergent adverse events, Physical examination and 4 more. Planned start Jul 2024; status: authorised.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on 2024-514466-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514466-38-00.